EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Exploring Novel E3 Ligases and Neosubstrates for Molecular Glue Degraders and Therapeutic Applications in Cancer

Ji Hoon Jang, Joo-Young Kim, Tae-Jin Lee

Oncology Research · 2026 · 34 (6) · 1-10

DOI: 10.32604/or.2026.073660 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Research, 2026. Verfasst von Ji Hoon Jang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, College of Medicine, Yeungnam University, Daegu, Republic of Korea. Hauptthemen laut MEDLINE: Ubiquitin-Protein Ligases, Neoplasms, Antineoplastic Agents. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin-Protein LigasesNeoplasmsAntineoplastic AgentsHumansProteolysisAnimalsSubstrate Specificity

Stichwörter der Autor:innen

E3 ligase substrateE3 ubiquitin ligasesMolecular glue degradersanticancer agent

Substanzen

Ubiquitin-Protein LigasesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Anatomy, College of Medicine, Yeungnam University, Daegu, Republic of Korea.

Zitieren

APA

Jang, J. H., Kim, J. Y., & Lee, T. J. (2026). Exploring Novel E3 Ligases and Neosubstrates for Molecular Glue Degraders and Therapeutic Applications in Cancer. Oncology Research, 34(6), 1-10. https://doi.org/10.32604/or.2026.073660

Vancouver

Jang JH, Kim JY, Lee TJ. Exploring Novel E3 Ligases and Neosubstrates for Molecular Glue Degraders and Therapeutic Applications in Cancer. Oncology Research. 2026;34(6):1-10. doi:10.32604/or.2026.073660

BibTeX
@article{Jang2026,
  author = {Jang, Ji Hoon and Kim, Joo-Young and Lee, Tae-Jin},
  title = {Exploring Novel E3 Ligases and Neosubstrates for Molecular Glue Degraders and Therapeutic Applications in Cancer},
  journal = {Oncology Research},
  year = {2026},
  volume = {34},
  number = {6},
  pages = {1--10},
  doi = {10.32604/or.2026.073660}
}
Kostenlos starten →